Personalized Medicine for Metastatic Prostate Cancer: The Paradigm of PARP Inhibitors.

[1]  C. Redfern,et al.  Rucaparib or Physician's Choice in Metastatic Prostate Cancer. , 2023, The New England journal of medicine.

[2]  D. Generali,et al.  DNA repair deficiency as circulating biomarker in prostate cancer , 2023, Frontiers in Oncology.

[3]  N. Lawrentschuk,et al.  Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short? , 2022, Nature Reviews Urology.

[4]  D. Generali,et al.  Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment , 2022, Expert opinion on therapeutic targets.

[5]  M. Loda,et al.  Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984 , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Bryce,et al.  Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. , 2022, European urology.

[7]  K. Cadoo,et al.  PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures , 2022, Cancers.

[8]  E. Antonarakis,et al.  1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study , 2022, Annals of Oncology.

[9]  C. Redfern,et al.  Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. , 2022, The Lancet. Oncology.

[10]  M. Burotto,et al.  Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial , 2022, Journal for ImmunoTherapy of Cancer.

[11]  G. Attard,et al.  Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges , 2022, British Journal of Cancer.

[12]  A. Armstrong,et al.  Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, NEJM evidence.

[13]  J. Randall,et al.  The Prognostic Significance of Homologous Recombination Repair Pathway Alterations in Metastatic Hormone Sensitive Prostate Cancer. , 2022, Clinical Genitourinary Cancer.

[14]  N. Agarwal,et al.  TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus ENZA in patients with DDR gene–mutated, metastatic castration-sensitive prostate cancer (mCSPC). , 2022, Journal of Clinical Oncology.

[15]  A. Marchetti,et al.  Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies , 2022, ESMO open.

[16]  L. Appleman,et al.  Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. , 2022, European urology.

[17]  E. Maiello,et al.  The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy , 2022, International journal of molecular sciences.

[18]  David C. Smith,et al.  Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). , 2022, Journal of Clinical Oncology.

[19]  A. Armstrong,et al.  PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). , 2022, Journal of Clinical Oncology.

[20]  J. Carles,et al.  A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). , 2022, Journal of Clinical Oncology.

[21]  H. Scher,et al.  Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. , 2022, The Lancet. Oncology.

[22]  A. Lau,et al.  ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib , 2022, Cancer research.

[23]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[24]  C. Higano,et al.  Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study , 2021, Clinical Cancer Research.

[25]  F. Saad,et al.  Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[26]  S. Pettitt,et al.  Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial , 2021, Cancer discovery.

[27]  K. Pantel,et al.  Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.

[28]  Ronald C. Chen,et al.  CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC). , 2021 .

[29]  V. Conteduca,et al.  New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer , 2021, Cells.

[30]  H. G. van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2020, European urology.

[31]  F. Saad,et al.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[32]  E. Antonarakis,et al.  BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike? , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Higano,et al.  Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Bertaut,et al.  Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment , 2020, BMC Cancer.

[35]  A. Tutt,et al.  Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. , 2020, Cancer discovery.

[36]  C. Parker,et al.  Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Anne E. Calvaresi,et al.  Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Chirivella,et al.  PROREPAIR-A: Clinical and molecular characterization study of prostate cancer (PC) patients with and without previously known germline BRCA1/2 mutations. , 2020 .

[39]  F. Saad,et al.  Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.

[40]  F. Feng,et al.  Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study , 2020, Clinical Cancer Research.

[41]  N. Tunariu,et al.  Genomics of lethal prostate cancer at diagnosis and castration resistance , 2019, The Journal of clinical investigation.

[42]  N. Tunariu,et al.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[43]  C. Drake,et al.  Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  A. Sboner,et al.  PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer , 2019, Clinical Cancer Research.

[45]  J. Ledermann,et al.  Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  A. D'Amico,et al.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[47]  A. Semjonow,et al.  BRCAness in prostate cancer , 2019, OncoTarget.

[48]  S. Fröhling,et al.  Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance , 2019, Cold Spring Harbor molecular case studies.

[49]  S. Ramaswamy,et al.  Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models , 2019, Scientific Reports.

[50]  Wei Tang,et al.  Targeting NPRL2 to enhance the efficacy of Olaparib in castration-resistant prostate cancer. , 2019, Biochemical and biophysical research communications.

[51]  P. Meltzer,et al.  Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations , 2018, Journal of Immunotherapy for Cancer.

[52]  G. Hatch,et al.  HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells , 2018, Molecular oncology.

[53]  G. Mills,et al.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.

[54]  James X. Sun,et al.  BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. , 2018, Cancer discovery.

[55]  A. D’Andrea.  Mechanisms of PARP inhibitor sensitivity and resistance. , 2018, DNA repair.

[56]  F. Saad,et al.  Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  P. Ott,et al.  Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  F. Saad,et al.  Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. , 2018, The Lancet. Oncology.

[59]  A. Ashworth,et al.  Synthetic lethal therapies for cancer: what’s next after PARP inhibitors? , 2018, Nature Reviews Clinical Oncology.

[60]  M. Gleave,et al.  Clinical and molecular features of treatment‐related neuroendocrine prostate cancer , 2018, International journal of urology : official journal of the Japanese Urological Association.

[61]  A. Ashworth,et al.  Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. , 2017, Cancer discovery.

[62]  A. Chinnaiyan,et al.  Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. , 2017, Cancer discovery.

[63]  S. Tavaré,et al.  Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer , 2017, Nature Communications.

[64]  H. Wu,et al.  CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  P. Schirmacher,et al.  Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. , 2017, Seminars in oncology.

[66]  Wenjun Chang,et al.  Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.

[67]  M. Lieber,et al.  Non-homologous DNA end joining and alternative pathways to double-strand break repair , 2017, Nature Reviews Molecular Cell Biology.

[68]  G. Walker,et al.  Mechanisms of DNA damage, repair, and mutagenesis , 2017, Environmental and molecular mutagenesis.

[69]  Wei Guo,et al.  BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer , 2017, Oncotarget.

[70]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[71]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[72]  K. Jensen,et al.  Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance , 2017, Clinical Cancer Research.

[73]  J. Li,et al.  Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer , 2017, Molecular Cancer Therapeutics.

[74]  R. Simon,et al.  Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness , 2016, EMBO reports.

[75]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[76]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[77]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[78]  R. Fishel,et al.  Mismatch repair during homologous and homeologous recombination. , 2015, Cold Spring Harbor perspectives in biology.

[79]  V. Giranda,et al.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer , 2014, Investigational New Drugs.

[80]  Y. Pommier,et al.  Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.

[81]  Alan Ashworth,et al.  Mechanisms of resistance to therapies targeting BRCA-mutant cancers , 2013, Nature Medicine.

[82]  A. Ashworth,et al.  Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor , 2013, The Journal of pathology.

[83]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[84]  S. Powell,et al.  BRCA1 and BRCA2: different roles in a common pathway of genome protection , 2011, Nature Reviews Cancer.

[85]  Rochelle L. Garcia,et al.  Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Y. Miki,et al.  Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. , 2010, Molecular cell.

[87]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[88]  V. O'shea,et al.  Base-excision repair of oxidative DNA damage , 2007, Nature.

[89]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[90]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[91]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[92]  Wolf-Dietrich Heyer,et al.  Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.